Insulet (PODD) Expected to Release Quarterly Earnings on Wednesday

Insulet (NASDAQ:PODD) is projected to issue its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Insulet to post earnings of $1.59 per share and revenue of $832.71 million for the quarter. Insulet has set its FY 2026 guidance at 6.460- EPS. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:00 AM ET.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.47 by $0.19. The business had revenue of $801.70 million for the quarter, compared to the consensus estimate of $787.39 million. During the same quarter last year, the business posted $1.17 EPS. The business’s revenue was up 23.5% compared to the same quarter last year. On average, analysts expect Insulet to post $6.51 EPS for the current fiscal year and $7.71 EPS for the next fiscal year.

Insulet Trading Up 0.4%

Shares of NASDAQ PODD opened at $149.83 on Wednesday. Insulet has a 12 month low of $126.40 and a 12 month high of $354.88. The firm has a market capitalization of $10.39 billion, a price-to-earnings ratio of 28.01 and a beta of 1.11. The business has a 50-day moving average of $140.82 and a 200-day moving average of $181.92.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Stifel Nicolaus lowered their target price on shares of Insulet from $225.00 to $180.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Barclays raised shares of Insulet to a “hold” rating in a research note on Wednesday, October 7th. Raymond James Financial reissued an “outperform” rating and issued a $180.00 price target on shares of Insulet in a report on Thursday, August 6th. Weiss Ratings reissued a “sell (d+)” rating on shares of Insulet in a report on Monday, September 21st. Finally, Benchmark lowered their price objective on shares of Insulet from $250.00 to $185.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. Thirteen research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $186.68.

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.